







































PD-L1 – inhibitors in neuroendocrine neoplasia
Results from a real-life study
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Abstract
Immune check-point inhibitors (ICIs) have changed our view on how to treat cancer. Despite their approval in treatment of many
different cancers, efficacy of immune check-point inhibitors (ICI) in neuroendocrine neoplasia is limited and poorly understood.
Established treatment options of neuroendocrine tumors (NET) and neuroendocrine carcinomas (NECs) are based on surgery,
tumor-targeted medical treatments, Peptide Receptor Radionuclide Therapy (PRRT), and locoregional therapies. However, in many
patients these treatments lose efficacy over time, and novel therapies are urgently needed. We report on 8 patients diagnosed with
neuroendocrine neoplasms (NEN) that were treated with ICI (pembrolizumab, avelumab, nivolumab plus ipilimumab) as salvage
therapy. In this cohort, we observed tumor response with partial remission in 3 patients and stable disease in 1 patient. Four patients
showed progressive disease. Of note, responses were observed both in PD-L1 positive and PD-L1 negative patients. Here, we
discuss clinical courses of these patients in the context of available literature to highlight limitations and drawbacks currently
preventing the use of ICI in routine management of patients with NEN.
Abbreviations: AML = acute myeloid leukemia, ASCO = American Society of Clinical Oncology, CAP/TEM = capecitabin/
temozolomide, CT = computed tomography, CTCAE = Common Terminology Criteria for Adverse Events, EORTC = European
Organization for Research and Treatment of Cancer, GEP-NEN = gastroenteropancreatic neuroendocrine neoplasms, GERD =
gastroesophageal reflux disease, i.v. = intravenously, ICI = immune check-point inhibitors, MiNEN = mixed neuroendocrine non-
neuroendocrine neoplasm, MMR =mismatch-repair, MRI =magnetic resonance imaging, NEC = neuroendocrine carcinoma, NEN
= neuroendocrine neoplasms, NET = neuroendocrine tumors, NSE = neuron specific enolase, POLE = DNA polymerase epsilon,
PRRT = Peptide Receptor Radionuclide Therapy, QoL = quality of life, SCLC = small cell lung carcinoma, SIRT = selective internal
radiation therapy, SSA = somatostatin analogue, SSR = somatostatin receptor, STZ/5FU = streptozotocin/5-fluorouracil, TACE =
transarterial chemoembolization, TAE = transarterial embolization, WHO = World Health Organization.
Keywords: immune check-point inhibitors, neuroendocrine tumor, PD-L1, response, survival
1. Introduction
Neuroendocrine neoplasms (NEN) represent an uncommon
disease group that originates from the diffuse neuroendocrine
system with an incidence of 7/100,000 and a prevalence of 40/
100,000 in most countries.[1] According to the World Health
Organization (WHO), NEN are subclassified based on their Ki-
67 proliferation index and histological differentiation into low
(grade 1; G1), intermediate (grade 2; G2), and high (G3) grade
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NEN.[2] The latter are further subdivided into neuroendocrine
tumors (NET G3) and NEC based on differences in cell
morphology, proliferation, response to chemotherapy, as well
as patients’ outcome.[3] In most cases, abdominal NEN are
localized in ileum, pancreas, or stomach, extrabdominal
locations (e.g., thoracic, genitourinary) are comparatively rare.
Patients display a 5-years and 10-years survival of 90% and 63%
(ileum), 69% and 62% (pancreas), or 85% and 56% (stomach),
respectively.[4]
Current guidelines for the treatment of advanced NET
recommend antiproliferative therapy with somatostatin ana-
logues, Peptide Receptor Radionuclide Therapy (PRRT), or
systemic therapies including streptozotocin, temozolomide,
everolimus, or sunitinib.[5,6] In case of advanced NEC,
platinum-based chemotherapeutic regimens represent the stan-
dard of care.[7,8] Despite the fact that patients with NET or NEC
in almost all cases display an initial response to therapy, many
patients develop resistance at early time-points during the course
of disease and have only limited prognosis. Hence, alternative
therapies are needed.
The recent introduction of immune checkpoint inhibitors has
changed treatment algorithms for many patients, including many
types of gastrointestinal cancers.[9] PD-1/PD-L1 is the best
studied immune check-point in the context of cancer.[10] PD-1
represents an inhibitory receptor, which is found on different
immune cells including T- and B-cells as well as natural killer
cells.[10] Binding of PD-1 to PD-L1 activates the receptor
complex, leading to downregulation of immune cell activation,
proliferation, survival, and cytokine production.[11] While, under
physiological conditions, PD-1/PD-L1 protects normal tissue
against recognition by the immune system, tumor cells upregulate
expression of PD-L1 as a mechanism to evade the immune
response, allowing the tumor to grow and to develop metastases
in the course of disease.[12,13] Recently, specific inhibitors of the
PD-1/PD-L1 system have been successfully used for the treatment
of different malignancies including lung cancer, malignant
melanoma, and hepatocellular carcinoma, just to name a
few.[14] However, in the context of NEN, only very few data
are available. Pembrolizumab and spartalizumab have been
tested in patients with NEN, but revealed an overall limited
antiproliferative activity at least in non-selected patients.[15–18]
Thus, many authors concluded that a better identification of
patients with a high likelihood for tumor response before
treatment will be mandatory before immune check-point
inhibitors can be used regularly in the clinical management of
patients with NET.[19] Avelumab is an agent that has been largely
studied in Merkel cell neuroendocrine tumors being approved as
first- and second-line treatment of adult Merkel cell carcinoma
since September 2017.[20,21]
Here we report a real-life study of 8 NEN-patients that have
been treated at our outpatient unit with immune check-point
inhibitors (ICI) (pembrolizumab, avelumab, nivolumab plus
ipilimumab) as salvage therapy and discuss these cases in the
context of available literature.
2. Patients and methods
2.1. Study design and study population
The retrospective study was conducted in a tertiary health care
center that provides advanced specialty care to patients with
NEN. Our NEN database comprises 612 patients with
histologically proven diagnosis of NEN from 2008 to 2019 for
cases of neuroendocrine tumors and neuroendocrine carcinoma
treated with PD-L1 inhibitors. The database includes information
on primary and metastatic tumor localizations, histology,
including mitotic rate or Ki67 proliferation index, diagnostic
methods used for detection of primary and metastatic tumors,
classification according to staging and grading as recently
described.[22] We could identify 8 patients fulfilling our inclusion
criteria (patients characteristics are given in Table 1, individual
treatment schedules are summarized in Table 2, the individual





Patients included in our study had to fulfill the following criteria:
 diagnosis of NEN according to WHO classification 2010,[2]
 failure of standard treatment, which is defined as failure after
guideline-based chemotherapy, PRRT radio- and/or brachy-
therapy,[6,23]
 ICI treatment at our institution between 2008 and 2019.
Data were extracted from electronic medical charts into a
standardized case report form. The study protocol was reviewed
and approved by the institutional ethics committee (ethical
approval number EA1/229/17) and was done in accordance with
the Declaration of Helsinki.
For classification of NEN the grading system according to
WHO classification 2010 was used.[2] Assessment of disease
progression was performed according to radiological imaging
modalities (computed tomography (CT), MR) and evaluated
according to objective response evaluation criteria (RECIST 1.1).
In some cases, we used quantitative functional imaging
evaluation (FDG-PET-CT, DOTATOC PET-CT, somatostatin
receptor scintigraphy). Adverse events were evaluated and graded
according to Common Terminology Criteria for Adverse Events
(CTCAE).[24] Quality of life (QoL) was assessed regularly (at least
every 6 months) based on standardized questionnaires of the
European Organization for Research and Treatment of Cancer
(EORTC).
For literature review, PUBMED and ClinicalTrials.gov were
searched using a combination of the following keywords:
neuroendocrine neoplasia, carcinoid, neuroendocrine carcinoma,
mutational load, PD-1, PD-L1, nivolumab, pembrolizumab,
ipilimumab, avelumab. Published literature was reviewed with
respect to demographic data (age, sex) as well as clinical features
including metastases, symptoms, complications, treatment, and
diagnostic methods.
3. Individual case presentation
We present a series of 8 patients with histologically confirmed
diagnosis of neuroendocrine neoplasms, who were treated at our
outpatient unit with ICI after failure of standard therapies (as
defined in Section 2). Patient characteristics and therapy schedules
(including therapy response and therapy-associated side effects)
are provided in Tables 1 and 2. The individual course of disease is
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3.1. Case 1
A 49-year-old male patient was diagnosed with a NET G2 of the
larynx in April 2010.
The patient initially presented with hoarseness to his
otorhinolarnygologist, who detected a tumor of the left ary
cartilage during laryngoscopy. Subsequently, local resection of
the left ary cartilage was performed. After more than 2 years of
tumor free survival, a relapse of the primary tumor with
synchronous lymph node (cervical, hilar, mediastinal) and
pulmonary metastases became apparent in August 2012. Two
weeks later, the patient was admitted to right neck dissection with
lymph node resection. Histological and immunohistochemical
analysis of the resected tumor and lymph nodes revealed a
moderately-differentiated NET with expression of synaptophy-
sin, chromogranin A, CK7, pan-cytokeratin, and negativity for
TTF-1, CK5/6. Ki-67 was up to 12%. Surgery was followed by
15 cycles temozolomide monotherapy, which resulted in stable
disease according to RECIST until follow-up revealed progressive
disease with appearance of testicular metastases in November
2014. Subsequently, the patient underwent right orchiectomy,
followed by FOLFOX-based chemotherapy,[25,26] which had to
be discontinued after 12 cycles due to peripheral motor
neuropathy Grade 2 according to CTCAE.[24] In October
2016, after failure of everolimus (10mg/day, given between
June and September 2016), combination chemotherapy with
capecitabine/temozolomide (CAP/TEM[27]) was initiated. In
parallel, stereotactic radiation therapy of a newly diagnosed
orbital metastasis and resection of a small cutaneous metastasis
on the right upper arm were performed. Molecular analysis of
resected tumor tissue showed several single nucleotide variants
(SNV) within the DNA polymerase epsilon (POLE) gene, several
mutations in DNA repair genes such as BRCA1, BRACA2,
CHEK2, as well as HRASmutations. Since POLE gene mutations
are associated with hypermutations, which are a positive
predictive factor for ICI treatment response,[28–32] we initiated
therapy with pembrolizumab (2mg/kg, initially 150mg intrave-
nously (i.v.) every 21 days) in April 2017. Notably, this treatment
resulted in a partial remission according to RECIST 1.1 of
pulmonary, osseous, cutaneous, and cerebral metastases (Fig. 1a
and b). However, 3 months later a newly diagnosed cerebellar
metastasis was treated with stereotactic radiation therapy. Since
all other lesions showed enduring response to ICI, this therapy
was continued concomitantly. In the following year, the patient
showed stable disease. In October 2018, isolated progression of a
retrotracheal lymph node was detected and treated with
stereotactic radiation therapy. Based on the long lasting tumor
response of most of the metastases,[33] therapy with pembroli-
zumab was continued. When the patient presented with
hemoptysis in November 2019, a bronchoscopy was performed,
revealing a tumor stenosis of the right main bronchus, due to
metastatic infiltration. The patient also developed pneumonitis
Grade 2 according to CTCAE criteria as a side effect of ICI and
was treated successfully with systemic steroids. In this clinical
setting, we decided to discontinue treatment with pembrolizumab
in January 2020 and to switch the therapy regimen to CAP/
TEM.[27] Overall QoL during ICI treatment was reported
between good and excellent.
3.2. Case 2
A 63-year-old female patient was diagnosed with a NET G2 of
the right kidney in January 2005, which progressed into a NET
G3 with a Ki-67 up to 25% during course of disease.
The patient initially presented for a routine check-up to her
family practitioner, when a mass of the right kidney was detected
in sonography. Further clinical work-up including biopsy and a
DOTATOC/PET-CT revealed a somatostatin receptor (SSR)
positive moderately-differentiated NET of the right kidney. No
Table 1
Clinical, immunohistochemical, and molecular features of 8 patients with NEN with ICI.
No. Sex Age
Date of
diagnosis Diagnosis Distant metastases Ki67 Immunohistochemistry Molecular analysis






Synaptophysin +, chromogranin A+,
CEA+, EMA+, pan-cytokeratin+,
SMA, S100, CT31, PD-L1<
1%
Several SNV’s in POLE, BRCA1,
BRACA2, CHEK2, HRAS




Synaptophysin+, chromogranin A +,
NSE+, S 100+, vimentin+, CK7,
PD-L1 1%
No mutation in MSH2, MSH6,
PMS2, MLH1






Synaptophysin+, CD56+, CK20+, PD-
L1 30%
No mutation in MSH2, MSH6,
PMS2, MLH1
4 m 68 09/2010 Functional, NET G2/NEC G3,
gastric









ISL1, serotonin, PD-L1 5%
No mutation of HER2NEU, BRAF,
K-RAS, NRAS
MUC1 10%
5 f 44 04/2015 NET G3, pancreas head Liver, lymph node 26% Synaptophysin+, chromogranin A+,
SSTR2-, CDX2+, SSTR2, PD-
L1, RET+
No mutation in MSH2, MSH6,
PMS2, MLH1
6 m 46 07/2013 NET G1, pancreas head Liver, lymph node 2–3% Synaptophysin+, CD 56+, PDX1+,
CKMNF+, SSTR2 +, PD-L1
SNV in MSH2 06/18





Synaptophysin+, CD56+, PD-L1 SNV in MSH2, MSH6, POLE NR-
21, BAT-26, BAT-25, NR-24,
Mono-27
8 m 69 03/2017 NEC G3, duodenum Liver 80% Synaptophysin+, chromogranin A+,
CDX2+, CD56, TTF, insulin,
serotonin, CD3, CD20, PD-L1
5%
No mutation in EGRF, KRAS,
NRAS, BRAF, PIK3CA,
HER2NEU, EML4, ALK, RET,
ROS
NET=neuroendocrine tumor (NET), NSE=neuron specific enolase, SNV= single nucleotide variants, SSTR2=Somatostatin receptor 2.









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Özdirik et al. Medicine (2021) 100:1 Medicine
4
distant metastases could be found. Subsequently, a right
nephrectomy (in curative intention) was performed. Histological
and immunohistochemical analysis of the resected tumor showed
positive expression of synaptophysin, chromogranin A, vimentin,
neuron specific enolase (NSE), S100 protein, and negativity for
CK 7. Initially, Ki-67 was up to 5%. In the following years
recurrent lymph node metastases (07/07, 02/10) and a retrocaval
local relapse were detected and followed by retrocaval tumor
resection with partial resection of the inferior vena cava and
lymphadenectomy in April 2010. Further immunohistochemical
analysis revealed a Ki-67 up to 20%. DOTATOC/PET-CT
displayed newly diagnosed SSR positive liver metastases. Thus,
we initiated treatment with the somatostatin analogue lanreotide,
using its antiproliferative effects. In the following months staging
examinations showed stable disease until progression of liver
metastases and newly diagnosed bone metastases were detected
in April 2012. In this setting, we started treatment with
everolimus (10mg/day). Although therapy was initially well-
tolerated, it had to be reduced (5mg/day) and later discontinued
due to 2nd grade mucositis according to CTCAE[24] and
generalized pruritus. In the following months progressive disease
was detected. Considering the positive SSR status, we performed
PRRT Lut-177-DOTATATE (3 cycles), which led to stable
disease, but also to a drop in leucocyte count as well as recurrent
fever episodes. In the following months, the patient underwent 3
cycles of transarterial embolization (TAE) which resulted in
further progressive disease with a hepatic tumor load of 15% in
October 2015. In this clinical setting, further PRRT cycles were
refused by the patient. Staging examinations in June 2016
detected further progression. Thus, we initiated chemotherapy
with CAP/TEM[27] in June 2016, which had to be discontinued
due to further progression according to RECIST 1.1. in
September 2017. In the following months, we performed 2
more cycles of TAE, selective internal radiation therapy (SIRT) as
well as 1 cycle of brachytherapy in afterloading technique in
January 2019 which initially resulted in size reduction of liver
metastases. Immunohistological analysis of a biopsy taken during
afterloading in January 2019 displayed a Ki-67 of 25%, positive
PD-L1 expression, and no deficiency in mismatch repair proteins
(Fig. 2a–d). Nevertheless, in August 2019, further progressive
disease with size increase of liver metastases according to RECIST
1.1 and newly diagnosed subphrenic lesions was detected. In this
clinical setting, we initiated treatment with pembrolizumab (2
mg/kg, initially 150mg i.v. every 21 days) in October 2019.
Therapy was well-tolerated and staging examinations revealed
partial remission with a hepatic tumor load reduction of 40%
according to RECIST 1.1. after 3 months (Fig. 3a and b).
In February 2020, the patient is in a very well general condition
(ECOG 0), in partial remission and therapy is continuing. During
ICI treatment overall QoL was reported between good and
excellent.
3.3. Case 3
We have already reported[34] about a 55-year-old male patient,
who was diagnosed with a non-functional SSR-positive NET G2
of the pancreatic tail with invasion of the spleen and synchronous
SSR negative bilobar liver metastases, which progressed into a
NEC (Ki-67>50%) with additional metastasis to kidney,
adrenals, peritoneum, and lymph nodes.
After several treatment, attempts including first- and second-
line chemotherapy regimens (FOLFOX,[25,26] FOLFIRI,[35] CAP/
TEM[27]) as well as brachytherapy in afterloading technique,
disease progression continued. Based on a 30% PD-L1
expression in tumor cells, we initiated an off-label immunother-
apy with pembrolizumab (2mg/kg, initially 150mg i.v. every 21
days) in July 2017. In our previous case report, we demonstrated
partial remission until April 2018 with a reduction in hepatic
tumor size of at least 66% combined with an improvement of the
Karnofsky score rising from 60% to 100%. In further follow-up,
after administration of 13 cycles, a CT-scan of the chest indicated
disseminated bilateral ground glass opacities suggesting pneu-
monitis. Clinically, the patient was free of any symptoms. Thus,
we started oral steroid therapy and we temporarily discontinued
Figure 1. Axial contrast-enhanced CT-scan of abdomen and chest of a 49-year-old male patient (#1) with a NET G2 of the larynx with pulmonary, osseous,
cerebral, cutaneous, and subcutaneous metastases. Axial contrast enhanced CT-scans between September 2016 and October 2017 (09/16, 03/17, 07/17, 10/
17) show regression of subcutaneous (a) and pulmonary metastases (b) during therapy with pembrolizumab. Tumor lesions are indicated by white arrows.
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treatment with pembrolizumab. In October 2018, the patient
started to suffer from dyspnea and joint pain. Further clinical
work-up revealed bilateral rales and a recurrent pneumonitis
Grade 2 according to CTCAE[24] (Fig. 4a). Again, we
discontinued pembrolizumab and started anti-inflammatory
monotherapy with adalimumab (initial dose 160mg, after 2
weeks 80mg, after 4 weeks 40mg). After the resolution of the
pneumonitis (Fig. 4b), in January 2020 the 23rd cycle of
pembrolizumab was carried out, the patient is still in good
general health, being fully recovered from the therapy-related side
effects and still in partial remission. During treatment overall
QoL was rated good to excellent.
3.4. Case 4
We have already reported[36] about a 68-year-old male patient
who was initially diagnosed with a functional, gastric NET G2
(Ki67 5%) with liver, bone, lymph node metastases, and
peritoneal carcinomatosis in September 2010, which progressed
into a NEC with a Ki-67>70% during the course of disease.
Between 2010 and 2016 a combination of multiple therapies
such as octreotide, CAP/TEM,[27] hyperthermic intraperitoneal
chemotherapy (HIPEC), PRRT, transarterial chemoembolization
(TACE), and locoablative brachytherapy in afterloading tech-
nique were performed. Additionally, the patient underwent
several abdominal surgeries on his own request (as demonstrated
in Table 2). Despite the implementation of all possible therapies,
the patient continued to show progressive disease. Considering
the high mutational tumor load (2777 single nuclear variants and
21 indels), immunotherapy including vaccination with trans-
fected autologous tumor RNA between August 2013 and
December 2014 was started. Due to recurrent pneumonitis
Grade 2 according to CTCAE,[24] therapy had to be stopped and
was switched to atezolizumab (1200mg every 28 days)
accompanied by vaccination of transfected autologous tumor
RNA in August 2016 leading to stable disease until April 2017 as
we have already reported in our previous paper.[36]
In this clinical setting, combination therapy of ipilumimab and
pembrolizumab was continued resulting in stable disease. In
November 2017 a CT-scan of the chest indicated disseminated
bilateral ground glass opacities suggesting pneumonitis. Clinical
evaluation revealed pneumonitis Grade 2 according to
CTCAE.[24] Therapy was temporarily discontinued and oral
steroid therapy was initiated. Due to recurrent episodes of
extensive hyperglycemia treatment with adalimumab rather than
steroids (initial dose 80mg, maintenance therapy 40mg each 2
weeks) was successfully started. Despite stable disease of the
NET, increasing thrombocythemia necessitated bone marrow
Figure 2. Immunohistochemical expression of tumor cells of hepatic metastases of a 63-year-old female patient (#2), who was initially diagnosed with a NET G2 of
the right kidney, which progressed into a NET G3 during course of disease. H&E stain (20) of the tumor cells of hepatic metastases shows cells with moderate
nuclear pleomorphism, finely speckled chromatin and finely granular eosinophilic cytoplasm (a). Immunohistochemical staining (20) reveals a Ki-67 proliferation
index of 25% (b) few scattered cells with membranous PD-L1 expression (c) and no deficiency in mismatch repair proteins such as MSH6 (d).
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analysis leading to the additional diagnosis of acute myeloid
leukemia (AML) in 10/2019. The patient is currently receiving
specific treatment leading to remission so far. During treatment
QoL was reported to be between good and excellent.
3.5. Case 5
A 44-year-old female patient was diagnosed with a non-
functional NET G3 of the pancreatic head in April 2015.
The patient initially presented to our outpatient unit with painless
jaundice. Further clinical work-up including a multi-slice CT-scan
revealed a tumor of the pancreatic head.No distantmetastases were
found. Subsequent surgery with partial duodenopancreatectomy
and partial gastric resection was performed. Pathological work-up
of the resected tumor revealed a poorly differentiated neuroendo-
crine tumor. Immunohistochemical analysis showed expression of
synaptophysin, chromogranin, CDX2, while no SSTR2 was
detected. Ki-67 was 25%. Follow-up examinations did not show
any signs of recurrence until September 2015,whenmultiple hepatic
metastases were detected. Despite administration of several
chemotherapeutic regimens (STZ/5-FU,[37] CAP/TEM,[27] FOL-
FOX[25,26]) and later on everolimus (discontinued in July 2017) no
Figure 3. Axial contrast-enhancedMR-scans of the abdomen of a 63-year-old female patient (#2) with a NET G3 of the right kidney with liver and bonemetastases.
Axial contrast-enhanced MR-scans of the abdomen demonstrate hepatic metastases in segments 5, 7, and 8 (indicated by white arrows) before therapy initiation
with pembrolizumab in October 2019 (a). Axial MR of the abdomen in February 2020 reveals hepatic tumor load reduction of 40% according to RECIST 1.1. Hepatic
metastases in segments 5, 7, and 8 are indicated by white arrows (b).
Figure 4. Axial contrast-enhanced CT-scans of a 50-year-old male patient (#3) with a non-functional NET G2 of the pancreatic tail, who developed pneumonitis
during treatment with pembrolizumab. Axial contrast-enhanced CT-scan of the chest reveals disseminated bilateral ground glass opacities suggesting pneumonitis
after several cycles of treatment with pembrolizumab in October 2018 (a). Axial contrast-enhanced CT-scan in December 2018 demonstrates regression of the
ground glass opacities after initiation of treatment with adalimumab therapy and discontinuation of pembrolizumab therapy (b).
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sustained tumor responsewas achieved. PRRTwas impossible since
the tumor was negative for somatostatin receptor on imaging, this
was later confirmed by expression immunohistochemical
means.[38,39] Another tumor biopsy was taken and molecular
characterization of the tumor was conducted, revealing strong
expression of RET, no expression of PD-L1, while a loss of DNA
mismatch repair genes (MSH2, MSH6, PMS2, MLH1) was not
detected. Based on the overexpression of RET, treatment with
sunitinib was initiated; however, not associated with tumor
response. We, therefore, changed systemic therapy to salvage
therapywith pembrolizumab (2mg/kg, initially 150mg i.v. every 21
days) in March 2018. Unfortunately, in the following weeks, the
patient’s general condition deteriorated, going along with progres-
sive weight loss, increase in tumor pain, and loss of liver function,
finally resulting in patient’s death (June 2018).
3.6. Case 6
A 46-year-old male patient was diagnosed with a non-functional
NET G1 of the pancreatic head and synchronous liver metastases
in July 2013.
The patient initially presented for a routine check-up to his
family practitioner, when multiple liver metastases were detected
by liver sonography. The patient was referred to our outpatient
unit. Multi-slice CT-scan displayed a tumor of the pancreatic
head as well as bilobar liver metastases. A biopsy of the primary
tumor revealed a well-differentiated neuroendocrine tumor (G1).
Further immunohistochemical analysis showed expression of
synaptophysin, CD 56, PDX1, and CKMNF. Ki-67 was 2% to
3%. In line with SSR2A expression by immunohistochemical
analysis, DOTATOC/PET-CT imaging confirmed SSR positivity
for the primary tumor and liver metastases. Curative resection
rendered to be impossible due to extensive liver metastases.
Cytoreductive therapy with CAP/TEM,[27] streptozotocin/5-
fluorouracil (STZ/5FU),[37] PRRT, FOLFOX,[25,26] and finally
FOLFIRI[35] was conducted within the next years. Moreover,
targeted therapies with everolimus and sunitinib were performed
without sustained tumor response. Based on the detection of a
MSH2 mutation, treatment with avelumab (10mg/kg) was
initiated in September 2018. The patient did not suffer from any
specific side effects, but his general condition deteriorated rapidly
and the patient died from multiorgan failure in December 2018.
3.7. Case 7
We report about a patient diagnosed with a mixed neuroendo-
crine non-neuroendocrine neoplasm (MiNEN) of the colon in
April 2012.
A 44-year-old male patient presented initially with stool
irregularities leading to a colonoscopy revealing 2 adenomas in
the ascending and descending colon. The adenoma in the
descending colon was diagnosed as a MiNEN with the
neuroendocrine component graded as a NEC G3. The patient
underwent right hemicolectomy combined with ileotransversos-
tomy and left hemicolectomy. Immunohistochemical analysis
showed positive expression of synaptophysin, CD56, and NSE in
tumor cells. Surgery was followed by adjuvant chemotherapy
with cisplatin/etoposide. Follow-up CT in June 2015 displayed
an isolated diaphragmatic metastasis, which was surgically
removed. Three months later, staging revealed further progres-
sive disease with appearance of ileal lymph nodes as well as liver
and pleural metastases. In September 2016, chemotherapy was
startedwith FOLFOX[25,26] and later switched to FOLFIRI[35] due
to severe peripheral neuropathy. In the following months, the
patient was in a good general condition (ECOG0), showing stable
disease. As follow-up examinations revealed tumor progression,
diagnostic laparoscopy was performed. Molecular analysis of
obtained tissue samples revealed mutations in MSH2, MSH6,
POLE, and inNR-21, BAT-26, BAT-25,NR-24,Mono-27. PD-L1
expression was negative. Due to further progression, we initiated
treatmentwith pembrolizumab (2mg/kg, initially 150mg i.v. every
21 days) in March 2018. Follow-up examinations after 3 months
revealed stable disease. However, after 6 months of stable disease,
progressive disease was observed. Therefore, treatment with CAP/
TEM[27] was initiated in November 2018. Additionally, we
admitted the patient to radiotherapy of pleural metastases. In the
following years, staging examinations revealed stable disease. In
November 2019, progressive disease was detected. In February
2020, the patient was still alive. During treatment no relevant
impairment to QoL was reported.
3.8. Case 8
A 69-year-old-male patient was diagnosed in March 2017 with a
NEC G3 of the duodenum and synchronous liver metastases.
In March 2017, an upper endoscopy, which was performed as
work-up of an iron deficiency anemia, showed a tumorous lesion in
the duodenum. Several upper endoscopies between 2015 and 2017
had not revealed any pathological finding except gastroesophageal
reflux disease (GERD). Further radiological work-up including
multi-slice CT of chest and abdomen as well as an magnetic
resonance imaging (MRI) displayed a tumorous lesion of the
uncinate process extending to the horizontal portion of the
duodenum as well as multiple bilobar liver metastases (initial tumor
load 30%). Histological and immunohistochemical analysis of a
biopsy from the duodenal tumor revealed a neuroendocrine
carcinoma with strong expression of synaptophysin, chromogranin
and a slightly weaker expression of CDX2, confirming the
gastrointestinal origin of the primary tumor. Expression of
CD56, TTF1, insulin, serotonin was negative. Ki-67 was up to
80% resulting in a NEC G3. Between March 2017 and January
2018, the patient received systemic therapy with carboplatin and
etoposide, which was well-tolerated, but had to be changed to a
second-line therapy with FOLFOX[25,26] because radiological
follow-up revealed progressive disease. Due to polyneuropathy
Grade 2 according to CTCAE,[24] treatment with FOLFOX was
terminated and chemotherapy with FOLFIRI[35] was initiated.
Under this treatment further tumor progressionwas observed. Since
no “standard” third-line therapy is established for patients with
NEC, we performed a new liver biopsy revealing PD-L1 expression
in 5% of tumor cells and initiated an off-label therapy with
pembrolizumab (2mg/kg, initially 150mg i.v. every 21 days).
Further molecular analysis (comprising EGRF, KRAS, NRAS,
BRAF, PIK3CA, HER2NEU, EML4, ALK, RET, ROS1) did not
detect any targetablemutation. InNovember 2018, pembrolizumab
was discontinued due to progressive deterioration in the patient’s
general condition. The patient succumbed to death due to
multiorgan failure in February 2019.
4. Review of the literature and discussion of
results
We report a case series of 8 patients with histologically confirmed
diagnosis of NEN who were treated at our institution with ICI as
Özdirik et al. Medicine (2021) 100:1 Medicine
8
salvage therapy. According to the 2012 WHO classification, 4
patients (#1,2,5,6) suffered from awell/moderately-differentiated
NET and 4 patients (#3,4,7,8) suffered from a neuroendocrine
carcinoma. Five patients displayed PD-L1 positive tumors. All
patients described within this case series were lacking standard
treatment options and were treated as “salvage” therapy with
check-point inhibitors. Based on the efficacy of these substances
in other malignant diseases, we hypothesized that at least a
subgroup of patients with NEN might benefit from check-point
inhibition in this clinical setting. Since no other treatment option
existed, it seemed reasonable to initiate therapy, despite the lack
of a reliable marker for identification of patients, who might
particularly benefit from treatment. Analyzing the clinical course
and response of patients treated with ICI, may help to identify
parameters facilitating the selection of patients benefiting from
the therapy.
All our patients received first- and second-line chemotherapies
according to their primary tumor, which had to be discontinued
due to tumor progression or therapy-associated side effects. Due
to the extent of the primary tumor, curative surgery could not be
performed in 3 cases (#3,6,8). Liver metastases of 3 patients
(#2,3,4) were considered accessible for locoregional procedures.
Radiation therapy was performed in 3 cases. Three patients
(#2,4,6) with SSR positive tumors received PRRT. Importantly,
we conducted molecular analysis in all patients before ICI
treatment was initiated. Mutations in DNA Mismatch Repair
Proteins (#6,7) and POLE gene (#1,7) were detected in 2 patients,
respectively. We treated 6 patients with pembrolizumab mono-
therapy, 1 patient with avelumab (#6), and 1 patient with a
combination therapy with pembrolizumab and ipilumimab
accompanied by vaccination of transfected autologous tumor
RNA. Three patients (#5,6,8) died due to tumor progression
shortly after initiation of ICI treatment. In 4 patients (#1–4), ICI
treatment led to partial remission or stable disease. Three patients
suffered from therapy-related side effects such as recurrent
pneumonitis Grade 2 according to CTCAE[24] (#3,4), diarrhea,
sleep disorders, and asthma (#7) or joint pain/arthralgia (#3).
Patients presenting with recurrent pneumonitis not only required
steroid therapy but also therapy with adalimumab (#3,4).
We report about a highly selected population which had
exhausted all standard treatments. Since the treatment options
for progressive disease in NEN are limited and most patients still
do not benefit from treatment with PD-L1 inhibitors, it is
necessary to identify markers that could have predictive value for
a clinical benefit. We demonstrate a clinical benefit in some
patients with PD-L1 negative tumor. Thus, our case series suggest
that a response to the PD-L1 inhibitor pembrolizumab in NEN is
independent of PD-L1 expression, which is similar to the results
from Keynote-158 but in contrast to small cell lung cancer, in
which PD-L1 expression is already described as an approved
marker for durable therapeutic response.[40] According to the
latest update of NSCLC treatment guidelines of the American
Society of Clinical Oncology (ASCO), monotherapy with
pembrolizumab can be used in cases with PD-L1 expression
over 50%, highlighting the importance of PD-L1 expression. In
contrast, additional chemotherapy is needed in cases with lower
PD-L1 expression.[41] Along with PD-L1 expression, mismatch-
repair (MMR) deficiency and density of tumor infiltrating
lymphocytes are reported to be associated with a better
therapeutic outcome.[42] An expert group around Dung T. Le
analyzed response to therapy in MMR-deficient cancers across
12 different tumor types (e.g., colorectal carcinoma, endometrial
carcinoma, esophageal carcinoma, NEN) and found out that a
large proportion of mutant neoantigens in MMR-deficient
cancers make them sensitive to immune checkpoint blockade,
regardless of the cancers’ tissue of origin.[43] Nevertheless, our
patients with MMR-deficiency (#6,7) did not show any
therapeutic response. According to Mehnert et al, the presence
of a POLE mutation is associated with high mutational burden
and elevated expression of several immune checkpoint genes in
endometrial cancer.[32] Two of our case patients displayed SVP in
POLE gene: whereas patient #1’s gene analysis was correlated
with PR to ICI treatment, patient #7 showed further progressive
disease. Furthermore, we also noticed that all patients with
response to therapy showed a Ki-67 of at least 15% (2 of them
developed aNEC during course of disease (#3,4)), suggesting that
a better response is associated with a higher proliferation rate.
Obviously, our findings must be tested in larger populations.
The potential of immunological therapies has already been
demonstrated by several studies using IFN in patients with
neuroendocrine tumors. Administration of IFN, both as mono-
therapy and in combination with somatostatin analogue (SSA),
led to both antiproliferative and anti-secretory effects. As an
example, the expert group Arnold et al studied interferon plus
octreotide (n=54) versus octreotide alone (n=51) in 105
gastroenteropancreatic tumor patients. The median survival
was 54 months in the combination arm vs 32 months in the
octreotide only arm. Despite this difference not reaching
statistical significance, the study highlights that immune-
oncological therapies might be used in patients with NEN.[44]
Modern immunotherapy consists of check-point-inhibitors that
might help to overcome mechanisms by which cancer cells evade
immune response. Immune checkpoints represent a class of
receptors or ligands, which once activated, repress T-cell response
against cancer cells (Fig. 5). In turn, antibodies against these
immune checkpoints might activate the immune system to re-
recognize these tumor cells as foreign.
The role of immune checkpoint inhibitors in the context of
neuroendocrine neoplasms is currently poorly understood.
Individual case reports provided the basis for the investigation
of the efficacy and safety of this substance class also in NEN.
Regarding NET, recently the results of the multi-cohort phase 1b
KEYNOTE-028 study (NCT02054806) were reported, which
enrolled small intestine/carcinoid- (n=25) and pNET-patients
(n=16) with PD-L1 positive tumors after failure of standard
therapy, respectively. Notably, out of 276 screened patients only
36% displayed PD-L1 positive tumors.[16] In contrast, our case
series features both patients with PD-L1-positive and PD-L1-
negative expression. Within Keynote-028, patients received
pembrolizumab at a dose of 10mg/kg every 2 weeks, which is
very similar to the treatment used in our patients. The efficacy of
the ICI treatment was moderate with 3 small intestine/carcinoid
patients (12%) and 1 pNET patient (6%) displaying objective
responses. Stable disease was achieved in 60% (n=15) and 88%
(n=14) of the patients.[16] Interestingly, we observed tumor
response with partial remission in 3 patients, in which PD-L1
staining revealed positive expression in 30%, 1%, and<1% (can
be considered negative PD-L1 expression according to keynote-
028 criteria) of tumor cells. Stable disease was detected in 1
patient with positive PD-L1 expression in 5%of tumor cells. Four
patients showed progressive disease, only 1 of them presented
with PD-L1 positivity in more than 5% of tumor cells. Based on
data from KEYNOTE-028, the phase II basket KEYNOTE-158
(NCT02628067) study was launched to analyze antitumor
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activity of pembrolizumab in 107 patients with well- and
moderately-differentiated NET of the lung, appendix, small
intestine, colon, rectum, or pancreas that progressed on≥1 line of
standard therapy. After a median follow-up of 18.6 months, an
ORR of 3.7% with 0 CR and 4 PR (3 pancreatic and 1
gastrointestinal) was achieved. 61 patients had SD as best
response.[18] Strikingly, the 4 responses were observed in patients
with PD-L1 negative tumors. Median PFS was 4.1 months and
median OS had not been reached, the 6-months survival-rate was
84.6%, further underlining the note that activity of pembroli-
zumabmonotherapy is rather limited and independent on the PD-
L1 status. As mentioned before, also in our cohort no difference
in tumor response was observed with regards to PD-L1 status.
In line with our report, Keynote-028 demonstrated that
pembrolizumab was associated with very moderate toxicity.
Nearly 70% (n=11) of pNET patients in the study did not suffer
from any therapy-related side effects. The most frequent side
effects were fatigue (n=6, 38%) and diarrhea (n=4, 25%),
followed by hypothyroidism (n=2, 13%) in both cohorts (pNET
and carcinoid). In contrast, 2 of our case patients suffered from
recurrent pneumonitis (#3,4), which led to interruption of
therapy, but could be treated successfully with steroid and
adalimumab therapy (Fig. 4a and b).
Similar to neuroendocrine tumors, a potential role of
immunotherapy was also analyzed in the context of neuroendo-
crine carcinoma. The potential role of ICI in NEC might be
derived from small cell lung carcinoma (SCLC), which is widely
regarded as a “model-disease” for NEC, where the PD-L1
inhibition demonstrated antitumor activity in terms of an
increased response rate and increased overall survival compared
to placebo. Regarding NEC, just recently Vijayvergia et al
reported data from 21 patients with metastatic high-grade
neuroendocrine neoplasms (Ki-67>20%) that were treated with
pembrolizumab after failure of a first line platinum/etoposide
doublet (NCT02939651). Pembrolizumab, though generally
well-tolerated, showed limited activity as a single agent in
this study (Disease Control Rate 19%, PFS 9.14 weeks, OS
15.4 weeks[45]). Similar results were found by Mulvey et al,
who analyzed the efficacy of pembrolizumab in 14 patients
with extrapulmonary poorly differentiated neuroendocrine
carcinomas with progression on first-line chemotherapy
(NCT03136055). The disease control rate was 21% (3/14)
and median PFS 58 days.[17] Comparably unfavorable results
were reported from 21 patients with GEP NEC, who had
progressed on first-line of chemotherapy and were subsequently
treated with spartalizumab (NCT02955069). In these patients,
only very low response rates of 4.8% and stable disease rates of
14.3% were achieved,[15] highlighting the very limited activity of
single agent immunotherapy in neuroendocrine carcinoma. In
contrast to these data, 2 patients who showed positive response to
monotherapy with pembrolizumab suffering from NEC. In case
of patient #6, who was initially diagnosed with a NET G2 and
developed a NEC Ki-67>70% during the course of the disease,
stable disease was demonstrated during combined therapy with
pembrolizumab, ipililumab, and vaccination of transfected
autologous tumor RNA. Notably, our patient with DNA
mismatch protein deficiency, but lack of PD-L1 expression did
not respond to treatment with pembrolizumab.
Figure 5. Expression of immune checkpoint inhibitors on T-cells and cancer cells. Immune checkpoints such as PD1/PD-L1 represent a class of receptors or
ligands, which once activated, repress T-cell response against cancer cells (adapted from Fig. 1 in Ref.[13]).
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Combination immunotherapies have demonstrated superior
efficacy compared to single agent therapy across different
cancers. Recently the combination of atezolizumab plus
bevacizumab was tested in patients with well to moderate
differentiated progressive NET. Interestingly, this combination
was associated to improved response rates and survival
compared to monotherapies, highlighting the potential of
immunotherapies also in patients with NET.[46] The efficacy of
a combination therapy consisting of nivolumab and ipilumumab
was analyzed within the SWOG S1609, a phase II clinical basket
trial in patients with high-grade neuroendocrine tumors
(NCT02834013). The combination of ipilimumab plus nivolu-
mab demonstrated a striking ORR of 42%. Six-months
progression-free survival rate was 30% and the median overall
survival 11 months, respectively.[47] In summary, these data
clearly demonstrate, that while PD-L1 blocking antibodies given
as single agents have only limited activity in patients with NEC,
combination immunotherapies might significantly improve
patients’ prognosis and warrant further investigation.
5. Conclusion and future perspectives
Neuroendocrine neoplasia might be successfully treated – in very
selected cases – with check-point inhibitors such as pembroli-
zumab, avelumab, or a combination of nivolumab plus
ipilimumab. In patients after failure of standard therapies,
partial remissions as well as long lasting periods of stable disease
combined with an improvement of quality of life can be observed.
At present, molecular mechanisms leading to tumor response
upon administration of ICI are only poorly understood.
Although, the determination of PD-L1, MSI, and mutational
load allows the identification of at least 3 specific subgroups, an
unknown number of patients is missed possibly benefitting from
ICI. The estimated percentages of patients who are eligible for
and who respond to checkpoint inhibitor drugs are higher than
reported estimates for drugs approved for genome-driven
oncology but remain modest. Future research should explore
biomarkers to maximize the benefit of immunotherapy among
patients receiving it.
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